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Cell membranesThemechanismofmembrane disruption bymelittin (MLT) of giant unilamellar vesicles (GUVs) and live cellswas
studied using ﬂuorescencemicroscopy and two ﬂuorescent synthetic analogues ofMLT. The N-terminus of one of
these was acylated with thiopropionic acid to enable labeling with maleimido-AlexaFluor 430 to study the
interaction of MLTwith live cells. It was compared with a second analogue labeled at P14C. The results indicated
that the ﬂuorescent peptides adhered to the membrane bilayer of phosphatidylcholine GUVs and inserted into
the plasma membrane of HeLa cells. Fluorescence and light microscopy revealed changes in cell morphology
after exposure to MLT peptides and showed bleb formation in the plasma membrane of HeLa cells. However,
the membrane disruptive effect was dependent upon the location of the ﬂuorescent label on the peptide and
was greater when MLT was labeled at the N-terminus. Proline at position 14 appeared to be important for anti-
microbial activity, hemolysis and cytotoxicity, but not essential for cell membrane disruption.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Melittin (MLT) is a small membrane-active peptide [1] which
consists of 26 amino acid residues and is the major toxic component
of bee venom [2–4]. Some of its properties include being antimicrobial
[5], cytolytic [6,7], cationic (+5) and hemolytic [8,9]. The MLT peptide
has an amphipathic structure [10,11], a strong binding afﬁnity to lipid
membranes [12] and can exist in two orientations, parallel or perpen-
dicular to the membrane bilayer [13]. Furthermore, MLT is known to
induce changes in the integrity of plasmamembranes and lipid bilayers
resulting in pore and ion channel formation as well as vesicle deforma-
tion [4,14]. Pore formation is likely to be the result of perpendicular
insertion into the membrane while parallel orientation with the
membrane may be its inactive state [13,15]. However, the underlying
mechanism of membrane insertion and disruption upon MLT exposure
is unclear because its interaction with the membrane is dependent on
lipid bilayer composition [16] and peptide concentration [16,17].
To investigate the interaction between peptides and cell membranes,
which is a fundamental biological process involved in ion channel forma-
tion, cytolysis and signaling [18], membrane fusion and disruption [19],and endocytosis and exocytosis [20], various techniques have been
used including solid-state NMR spectroscopy [3,21], isothermal titration
calorimetry [22], ﬂuorescence [23,24] and circular dichroism (CD)
spectroscopy [25]. Previous investigations of the action of MLT on cell
membranes typically used synthetic model membranes rather than
biological membranes due to the complexity and heterogeneity of
biological membranes [26] as well as the deleterious hemolytic activity
of MLT in vivo [27].
Melittin also exhibits anticancer properties [28,29] that may be
mediated by the activation of the ubiquitous enzyme, phospholipase
A2 (PLA2) [30,31], which catalyzes hydrolysis of sn-2 acyl bond of phos-
pholipids resulting in the release of fatty acids [32]. This lipid–peptide
interaction leads to changes in structure of cell plasma membranes
causing vesiculation or blebbing [33]. These spherical outgrowths
from the plasma membrane are due to the detachment of plasma
membranes that are devoid of cytoskeleton material [34,35].
Here, we used light and ﬂuorescence microscopy to visualize the
interaction of MLT with model membranes and HeLa cells. Previous
ﬂuorescence-based studies on the interaction of melittin with
membranes used ﬂuorescence ﬂuorescent labels attached to the N-
terminal amine or lysine-7 [36]. In our study, two ﬂuorescent analogues
of MLT were prepared, the ﬁrst being a wild type MLT containing a
thiopropionic acid (TPA) residue at the N-terminus. Since proline at
2032 E. Jamasbi et al. / Biochimica et Biophysica Acta 1848 (2015) 2031–2039position 14 has been identiﬁed as an important amino acid for the
antimicrobial activity of MLT [37], the second MLT analogue had the
Pro replaced with a cysteine (C) residue. AlexaFluor 430 was attached
to TPA and cysteine using thiol-maleimide chemistry. Using these two
ﬂuorescent MLT analogues, we identiﬁed an important role for both
Pro14 and the N-terminal region for membrane disruptive activity and
cytotoxicity.
2. Materials and methods
2.1. Peptide synthesis
The two analogues of MLTwere prepared using Fmoc/tBu chemistry
via microwave irradiation-enhanced solid phase synthesis on a CEM
Liberty synthesizer [38,39]. Fmoc-protected amino acids were
purchased from GL Biochem (Shanghai, PRC). Fmoc removal was via
20% piperidine solution in dimethylformamide (DMF; Merck, Sydney,
Australia) at 75 °C for 3 min. Coupling of each HCTU/DIEA-activated
Fmoc-amino acid was performed at 75 °C for 5 min, except for cysteine
(50 °C for 5 min) and arginine (twice 50 °C for 5 min). In one MLT ana-
logue, 3-thiopropionic acid (TPA) (Sigma-Aldrich, Sydney, Australia)
was attached to the N-terminus of MLT leading to TPA-MLT. In the
second, Pro-14 was replaced by a cysteine leading to MLT(P14C). After
cleavage and simultaneous side-chain deprotection with triﬂuoracetic
acid (TFA) in the presence of scavengers as previously described [38,
39], the crude peptides were isolated by precipitation with ice-cold
ether and then puriﬁed by RP-HPLC using a Phenomenex C4 column
(particle size 5 μm, 4.6 × 150 mm), with gradient of 10% A to 90% B
30 min (A: 0.1% TFA (Auspep, Melbourne, Australia) in H2O; B: of 0.1%
TFA in acetonitrile). The TPA-MLT and MLT(P14C) were obtained in
overall yields of 15% and 18%, respectively, and 22% for native MLT
calculated from 0.1 mmol starting resin.
2.2. Maleimide functionalization of AlexaFluor 430
AlexaFluor 430 is commercially available only in NHS ester form
(Invitrogen, Sydney, Australia) which is amine-reactive. A major limita-
tion of using this reagent in solution is that the peptidewill be labeled at
multiple sites with free NH2 groups. To avoidmultiple labeling, the NHS
ester of AlexaFluor 430 can be selectively attached to the side chain of
Lys by solid phasemethods followingon-resinNε-deprotection. Howev-
er, this approach can consume a lot of dye which is very expensive [40].
Therefore, thiol-maleimide conjugation chemistry was used to attach
the AlexaFluor 430 dye to the MLT peptide in solution. Subsequently, a
coupling reaction was performed between the NHS-AlexaFluor 430
(1.4 μmol, 1 mg) and N-(2-aminoethyl)maleimide (Sigma-Aldrich,
Sydney, Australia) (1.68 μmol, 0.43 mg) in the presence of DIEA
(2.68 μmol, 0.05 μl) in DMF. The reaction was monitored by HPLC and
puriﬁed with a gradient of 10% A to 90% B leading to 53% yield of
Mal-AlexaFluor 430.
2.3. Conjugation of Mal-AlexaFluor 430 to MLT peptides
The presence of a TPA residue at the N-terminus of MLT (TPA-MLT)
enabled the attachment of Mal-AlexaFluor 430 to the thiol of TPA. For
the mutant analogue, MLT(P14C), the AlexaFlour 430 was attached to
the side-chain of the replaced cysteine residue. MLT(P14C) or TPA-
MLT and Mal-AlexaFluor 430 were dissolved separately in minimum
amount of MilliQ water. Then, the TPA-MLT or MLT(P14C) solution
(0.702 μmol, 2 eq) was added to Mal-AlexaFluor 430 (1.6 μmol, 1 eq)
solution drop by drop. The pH was adjusted to 7.4 using 0.2 M phos-
phate buffer. The reaction was completed in 30 min at room tempera-
ture. The peptides were then puriﬁed using a preparative RP-HPLC C4
column with a gradient of 35% A to 65% B for 30 min. The residual TFA
was removed by freeze-drying the peptide from dilute aqueous HCl.
Fig. 1 shows the MALDI TOF mass spectra and RP-HPLC proﬁles for thepuriﬁed peptides. 9.77 mg (40% yield) of Fluor-TPA-MLT (F-MLT) and
11 mg (45% yield) of MLT(P14C)-Fluor (MLT(P14C)-F) were obtained
from 3 mg of dye (Mal-AlexaFluor 430).
2.4. Circular dichroism (CD) spectroscopy
CD spectroscopy was used to probe the secondary structure and fold-
ing ofMLT peptides and to determine conformational changes upon addi-
tion of lipid vesicles. Phospholipids, palmitoyloleoylphosphatidylcholine
(POPC), palmitoyloleoylphosphatidylethanolamine (POPE) and palmi-
toyloleoylphosphatidylglycerol (POPG) were purchased from Avanti
Polar Lipids (Alabaster, USA). Cholesterol (Chol) was purchased from
Sigma-Aldrich (St Louis, USA). Multilamellar vesicles (MLVs) were
prepared by dissolving desired amounts of phospholipid ± Chol in
chloroform: methanol (3:1), after which the organic solvent was evapo-
rated under vacuum to obtain a lipid ﬁlm. The lipid ﬁlm was placed
under vacuum overnight to evaporate residual organic solvents. The
dried ﬁlm was resuspended in MilliQ water, homogenized, divided into
aliquots and then lyophilized for each experiment. Large unilamellar
vesicles (LUVs) were prepared by extruding MLVs through 100 nm poly-
carbonate membranes (Whatman Nuclepore, GE Healthcare, Sydney,
Australia) in 10 mM Tris buffer. The CD spectra were recorded on a
Chirascan-plus instrument (Applied Photophysics, Leatherhead, UK)
between 190 and 260 nm. The cell path length was 0.1 cm and all
measurements recorded at 25 °C [25]. Peptides were prepared in
10mM Tris buffer (pH 7.0) plus 10mMNaCl, and the ﬁnal concentration
was 10 μM. Helix content of peptide was calculated using the formula
max[θ]222 =−40,000 × [1−(2.5/n)] + (100 × T), where n is number of
amino acid residues and T is temperature in °C [41]. Percentage helicity
was calculated as 100 × [θ]222 / max[θ]222.
2.5. Giant unilamellar vesicles (GUVs)
GUVs were prepared by adding a desired amount of 0.1 M phos-
pholipid solution of dipalmitoylphosphatidylcholine (DPPC) or
dimyristoylphosphatidylcholine (DMPC) dissolved in chloroform to
a mixture of chloroform:methanol in a ratio of 9.8:1 [42]. To detect
themembrane bilayer of the GUVs, the red ﬂuorescent dye, BODIPY®
TR ceramide (Life Technologies, Australia) was added to the lipid so-
lution mixture at a ratio of 1:200 of dye:lipid. Filtered HEPES buffer
solution was carefully added to the organic phase of the mixture to
obtain 285 μM of vesicle sample solution. Vacuum rotary evapora-
tion was used to remove the organic phase (at 40 rpm), 40 °C and
100 mBar minimum pressure. The remaining aqueous GUV suspen-
sion was stored at room temperature for less than 1 week before
analysis. Speciﬁc volume of GUVs and MLT peptides (dissolved in
HEPES buffer) was transferred to a microscopy chamber (ibidi
GmbH, Germany) at a molar ratio of 1:27. The ﬂuorescent GUVs
were visualized using DeltaVision DV Elite™ Restorative Wide and
a 60× objective. The Alexaﬂour 430 was detected using the green
channel ﬁlter with excitation/emission wavelength of 490/510 nm
and the BODIPY® TR ceramide was detected using the red channel
ﬁlter (587/610 nm). Experiments were repeated 3 times.
2.6. Hemolytic activity of test peptides
The hemolytic activity of the test compounds was measured by
incubating (1–2) × 108 human red blood cells (RBC) with peptides in
phosphate buffered saline (PBS) in a ﬁnal volume of 70 μl for 6 min at
room temperature. After centrifugation at 210 ×g for 4 min, 2 μl of
supernatant was transferred into a 96-well plate and diluted with PBS
to a ﬁnal volume of 100 μl, after which the absorbance at 412 nm was
determined. Data were normalized against RBC lysed with sodium
dodecyl sulfate. Distilled water was used as the positive control and
PBS (pH 7.4) was used as the negative control, respectively. One HU
(hemolytic unit) was deﬁned as the minimum amount of dissolved
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Fig. 1. RP-HPLC and MALDI TOF MS traces of: MLT, F-MLT, MLT(P14C), and MLT(P14C)-F.
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analysis was carried out using univariate analysis of variance (ANOVA).
2.7. Cytotoxicity assay
Cell viability was determined using the CellTiter-Blue®Reagent
(Promega). This method is based on measuring the absorbance of re-
leased lactate dehydrogenase (LDH) from membrane-damaged cells
into the culture medium. Conversion of resazurin into ﬂuorescent
resoruﬁn product is the result of a 10 min coupled enzymatic assay.
The ﬂuorescence intensity is proportional to the number of lysed cells.
HeLa cellswere seeded in 12-well Nunc plates (Thermo Fisher Scientiﬁc,
Melbourne, Australia) at a density of 105 cells per well and grown in
Opti-MEM medium supplemented with 10% FCS, 1 U/ml Penstrep, and
1% GlutaMax (Life Technologies, Sydney, Australia) and maintained in
a humidiﬁed incubator at 37 °C, 5% CO2 for 24 to 48 h to allow the
cells to adhere to the plate. Cells were then treated with 0, 1, 5 and
10 μM MLT peptide for 24 h after which 100 μl of the conditioned
media was transferred to a 96-well ﬂat-bottom plate, and the cell
toxicity was measured using the CellTiter-Blue assay according to
manufacturer's instruction. The ﬂuorescence intensity was measured
at wavelengths for excitation (560 nm) and emission (590 nm) using
a plate reader (Thermo Fisher Scientiﬁc). Maximum ﬂuorescence inten-
sity was achieved by adding 2 μl of 9% Triton-X 100 to cells as a positive
control; cells incubated with PBS were the vehicle control.
2.8. Minimum inhibitory concentration (MIC)
MICs were determined in accordance with the Clinical Laboratory
Standards Institute (CLSI) document M7-A6. Brieﬂy, within 15 min of
the inoculum being prepared, each well of a 96-well microtiter tray
was inoculated with 50 μl suspension of a test bacterial strain. The
peptides were provided resuspended in 1 ml sterile distilled water
and diluted to a ﬁnal concentration of 250 μM in cation-adjustedMueller-Hinton Broth (CAMHB; Oxoid, Thermo Fisher Scientiﬁc,
Adelaide, Australia) and then aliquoted in 50 μl volumes into the wells
of the microtiter plates. For each test concentration, triplicate wells
were prepared and the solutions were then serially diluted 2-fold in
CAMHB. The ﬁnal concentration of each test compound ranged from
0.24 μMto 125 μM. All trayswere prepared in a Class II Biosafety cabinet
and were used within 30 min of preparation. The test bacteria used in
this study were: Staphylococcus aureus ATCC 29213, methicillin-
resistant S. aureus (MRSA) ATCC 43300, Escherichia coli ATCC 25922
and Pseudomonas aeruginosa ATCC 27853. All bacterial strains were
cultured on horse blood agar (HBA) before use. For S. aureus and
MRSA, a suspension equivalent to a 0.5 McFarland standard was
prepared by suspending colonies from an overnight HBA plate. For
E. coli and P. aeruginosa, three colonies were selected and inoculated
into 2.5 ml of brain–heart infusion broth (Oxoid, Basingstoke, UK),
and incubated at 37 °C with shaking for 4 h. The optical density of the
culture was then adjusted with sterile saline to be the same as that of
a 0.5 McFarland standard. The cultures were then diluted 1 in 100 in
CAMHB. Following inoculation, each well contained approximately
5 × 105 colony-forming units/ml. To prevent drying, each tray was
sealed with plastic tape before incubation overnight at 37 °C. Microtiter
wells were read visually for determination of the MIC. Two growth (no
added peptide), and two negative (uninoculated) control wells were
included for each test strain. The ﬁnal inoculum of each culture and its
purity were determined by plating on non-selective agar.
2.9. Fluorescence microscopy
HeLa cells were seeded at low density (25,000 cells per well) on
poly-D-lysine coated glass coverslips and grown in a 37 °C incubator
with 5% CO2 and allowed to adhere for 24 to 48 h. Before treatment
cells were washed with culture medium three times. MLT peptides at
0, 0.1, 0.3 and 1 μM concentrations were then added to some wells
and treatments for 30 and 60 min. Plasma membranes were stained
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Fig. 2. CD spectra for MLT (solid black line), MLT(P14C) (solid gray line), F-MLT (dashed
gray line) and MLT(P14C)-F (dashed black line) in: (A) Tris Buffer (pH 7.4) plus 1 mM
NaCl, (B) POPC/Chol, and (C) POPE/POPG with lipid:peptide ratio of 30:1, and peptide
concentration of 10 μM. (D) % α-helicity was calculated from the mean residue ellipticity
(MRE) values at 222 nmwavelength.Measurements were recorded at room temperature.
Mean residue ellipticity (MRE).
2034 E. Jamasbi et al. / Biochimica et Biophysica Acta 1848 (2015) 2031–2039using Cell Mask Deep Red dye (5 μg/ml) (Invitrogen, Australia) for
15 min. The cells were then gently washed with pre-warmed PBS,
then ﬁxed with 4% paraformaldehyde/PBS for 20 min, and washed
twice more with PBS before mounting the coverslips on a glass slide
using ProLong Gold antifade reagent (Invitrogen) [43]. Mounting
media were allowed to harden for at least 24 h before the slides were
imaged using the DeltaVision DV Elite™ Restorative Wide ﬁeld
Deconvolution Imaging System (Applied Precision, Mississauga,
Canada). The mean ﬂuorescence intensity of images was quantiﬁed by
using ImageJ software [NIH ver 1.47].
2.10. Light microscopy (LM)
Light microscopy was used to image the dynamic process and
uptake of MLT peptides by HeLa cells. The cells were seeded at a density
of 105 cells per well in 12-well Nunc plates (Thermo Fisher, Melbourne,
Australia) and grown in Opti-MEMmedia supplemented with 10% FCS,
1 U/ml Penstrep, and 1% GlutaMax and maintained in a humidiﬁed
incubator at 37 °C, 5% CO2 [44]. HeLa cells were treated with the MLT
peptides at 0.1, 0.3 and 1 μM concentrations and examined at 15, 30
and 60 min. Following treatment, the cells were imaged using a Leica
inverted microscope (Leica DM16000, Wetzlar, Germany) with a 40×
objective. Leica LAS AF Lite software was used to process the results.
3. Results and discussion
3.1. Peptide synthesis
Two analogues of MLT, a 26 amino acid peptide, (GIGAV LKVLT
TGLPA LISWI KRKRQQ)were chemically assembled. One had a substitu-
tion of P at position 14 to a C, MLT(P14C), and the other had TPA acylat-
ed to the N-terminus of MLT. The presence of such a judiciously-placed
thiol moiety within MLT allowed labeling by the maleimide of
AlexaFluor 430 to produce MLT(P14C)-F and F-MLT respectively. Both
peptides were greater than 98% pure as determined by RP-HPLC and
their molecular masses were conﬁrmed by MALDI TOF MS (Fig. 1).
Overall yield was 22% for MLT, 15% for TPA-MLT, 18% for MLT(P14C),
40% for F-MLT and 45% MLT(P14C)-F (yield for ﬂuorescent peptides
based on pure peptide used as startingmaterial). The calculated masses
(MLT 2846; F-MLT 3562; MLT(P14C) 2852 and MLT(P14C)-F 3477)
matched with the observed masses (MLT 2848; F-MLT 3562;
MLT(P14C) 2853 and MLT(P14C)-F 3478) (Fig. 1).
3.2. Circular dichroism (CD) spectroscopy of MLT peptides with LUVs
To investigate whether mutating the MLT peptide at position 14
altered its secondary structure, CD spectral analysis was performed in
the absence and presence of synthetic lipid preparations. The CD spectra
of the native MLT and the MLT(P14C) analogues showed that the pep-
tides adopted a random coil structure in 10 mM Tris buffer (pH 7.4)
plus 1 mM NaCl (Fig. 2A). While adding a AlexaFluor 430 label to the
N-terminus of the native peptide, F-MLT, did not alter its random coil
structure, attaching the AlexaFluor 430 to the substituted C residue in
mid-portion of the mutated MLT peptide MLT(P14C)-F, caused this
peptide to adopt an α-helical structure (Fig. 2A). The addition of
POPE/POPG (anionic) and POPC/Chol (zwitterionic) LUVs to the MLT
peptides resulted in a transition from random coil toα-helical structure
for the native MLT, the F-MLT and the mutant MLT(P14C) peptides
(Fig. 2B and C, respectively). However, the helical content of
MLT(P14C)-F decreased in the presence of these LUVs. All peptides
except for MLT-F were random coil in buffer and helical in the presence
of lipid systems. The helical content of the peptides was dependent on
the lipid composition of the LUV and both MLT and MLT(P14C) were
helical in both lipid systems. However, the helical content of MLT was
lower than that of MLT(P14C), which may be related to the role of
proline in peptide insertion in lipid bilayers [46]. As shown in Fig. 2D(summary of α-helix content), a comparison of MLT and F-MLT
revealed that F-MLT was more helical, which could be due to the pres-
ence of AlexaFluor 430 changing the polarity and hydrophobicity of
the peptide (as MLT(P14C)-F is more helical than MLT(P14C) in buffer
and POPE/POPG LUVs). The helicity of F-MLT increased in the presence
of POPC/Chol, which suggests that lipid order affected the structure of
peptides. MLT(P14C)-F helicity increased in the presence of POPE/
POPG (liquid disordered phase) but decreased in the presence of
POPC/Chol (more ordered) which indicated that lipid charge (and
order) has an effect on the peptide helicity.
3.3. Interaction of MLT peptides with giant unilamellar vesicles (GUVs)
Since MLT has a strong binding afﬁnity to lipid membranes [12], we
prepared spherical lipid membranes (GUV composed of either DPPC or
DMPC) and investigated the interaction of the MLT peptides with these
structures. Although the GUV size is dependent on experimental condi-
tions rather than peptide addition, the GUVs (red) formed spherical
structures with a typical diameter of around 40 μM in diameter for
both DPPC and DMPC GUVs (Fig. 3B). After addition of MLT peptides,
the ﬂuorescence intensity of the GUVs decreased (Fig. 3E), which may
be due to effect of peptide binding on the lipid bilayer. MLT has been
proposed to expand the lipid head group area when adsorbed to a
lipid bilayer, resulting in a decrease in bilayer thickness [45]. The native
F-MLT peptide internalized into the DPPC GUV preparation but failed to
(i) DPPC (ii) DMPC
Fig. 3. Synthetic GUVs incorporatedwith native andmutantMLT peptides. GUVs contained either (i) DPPC, or (ii) DMPC lipids. GUVs incorporatedwith (A–C)MLT, (D–F) F-MLT, and (G–I)
MLT(P14C)-F. The peptides were visualized in (A, D, G) green channel, (B, E, H) red channel, and in (C, F, I) combined green and red channels. Scale bar = 20 μm.
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Fig. 4. Hemolytic and cytotoxic activity of MLT peptides. (A) The concentration of MLT
peptide causing 50% hemolysis of RBC, N = 3, *P b 0.05 or **P b 0.01 vs. MLT, ##P b 0.01
vs. MLT(P14C), and (B) the cell viability of HeLa cells following MLT treatment at 0 μM
(striped bar), 1 μM (clear bar), 5 μM (gray bar) and 10 μM (black bar) was determined
by using the CTB assay after 24 h incubation with each test compound. N = 3, *P b 0.05
or **P b 0.01 vs. untreated cells. Results are mean ± SEM.
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of the DMPC (gel-ﬂuid phase transition ~23 °C) compared to DPPC
(gel-ﬂuid phase transition ~42 °C) [46]. Like the native F-MLT peptide,
the mutant MLT(P14C)-F peptide also internalized into the DPPC
GUVs but not in the DMPC GUVs (Fig. 3G–I). Since the GUVs remained
intact, both native and mutant MLT peptides appear to form pores in
the membrane and penetrate the multilayers of DPPC [47].
3.4. Hemolytic and cytotoxic activity of MLT peptides
Native MLT has been shown to have hemolytic activity in vivo
applications [27]. The concentration of the native MLT peptide causing
50% hemolytic activity was 5.0 ± 0.16 μM while only around half as
much (2.6 ± 0.15 μM) of the mutant MLT(P14C) peptide was required
to cause the same level of hemolysis of RBC (Fig. 4A). However, adding
the ﬂuorescent tag to either MLT analogue decreased hemolytic activity
by 2 and 4-fold for F-MLT and MLT(P14C)-F, respectively, with 10 μM
required for 50% hemolysis (Fig. 4A).
SinceMLThas been shown to be cytotoxic in various cancer cell lines
[29], we examined the dose response of the MLT peptides on HeLa cells
after 24 h of treatment. The native MLT peptide was signiﬁcantly toxic
for HeLa cells at 1 μM while the mutant and ﬂuorescently-labeled
peptides were not toxic at this concentration (Fig. 4B). These results
demonstrate that mutation of the proline at position 14 appears to
diminish the cytotoxicity of MLT peptides. At higher doses, 5 and
10 μM, all four MLT peptides were toxic and the extent of cytotoxicity
was similar (~40%).
3.5. Effect of MLT peptides on bacterial growth
The bacterial cell wall is responsible for protection against damaging
compounds [48,49]. The peptidoglycan layer is sandwiched between
the inner and outer cell membrane in Gram negative bacteria [48],
while the peptidoglycan layer is thicker in the cell wall of Gram positive
bacteria [50]. The MIC results for the MLT peptides against Gram
positive and Gram negative bacteria indicated that F-MLT was between
MLT and the MLT(P14C) mutants in activity; and had a similar trend as
MLT against the different bacteria (Table 1). The native MLT peptide
Table 1
Effect of MLT peptides on bacterial growth.
Bacterial strain MICa (μM)
MLT MLT(P14C) F-MLT MLT(P14C)-F
S. aureus ATCC 29213 3.9 62.5 15.6 N125
MRSA ATCC 43300 7.8 62.5 62.5 N125
E. coli ATCC 25922 15.6 N125 62.5 N125
P. aeruginosa ATCC 27853 31.3 N125 N125 N125
a Data are the mean of three determinations.
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Fig. 5. FluorescencemicroscopyofHeLa cells afterMLT treatment. (A) Untreated cells, were com
andwithMLT(P14C)-F at 0.1, 0.3, and 1 μM(E, F, andG, respectively). PeptideAlexaFluor 430wa
contrast (middle panel images) and Cell Mask Deep Red dye in the red channel (right panel im
2036 E. Jamasbi et al. / Biochimica et Biophysica Acta 1848 (2015) 2031–2039inhibited the growth of all four test strains at micromolar concentra-
tions. MLT displayed the highest potency for S. aureus (3.9 μM) and
2-fold less in turn for MRSA, E. coli and P. aeruginosa. The mutant
MLT(P14C) peptide showed a 15-fold decrease in potency to inhibit
bacterial growth. The addition of a ﬂuorescent tag to either the native,
F-MLT, or themutant, MLT(P14C)-F (N125 μM), decreased the inhibito-
ry activity of these peptides relative to the untagged peptides. Likely, the
polarity of thepeptides affects their ability to penetrate the cellwall. The
difference in the antimicrobial activity ofMLT andMLT(P14C) illustrates
the importance of the proline residue.Untreated cells
0.1 µM F-MLT
0.3 µM F-MLT
1.0 µM F-MLT
0.1 µM MLT(P14C)-F
0.3 µM MLT(P14C)-F
1.0 µM MLT(P14C)-F
pared to cells treated for 30minwith F-MLT at 0.1, 0.3, and 1 μM(B, C, andD, respectively);
s detected in the green channel (left image); theHela cell integritywas imagedusing phase
ages). Scale bar = 20 μM. Experiments were repeated 2–4 times and gave similar results.
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The appearance of microvesicles, derived from plasma membrane
and disconnection from cells, was observed after treatment with MLT
peptides, followed by separation of cell fragments (Fig. 5C–F).
Microvesicles are small bodies enclosed within the plasma membrane
and are secreted by different cell lines [51]. Comparing the images of
untreated cells with those treated with peptides revealed that plasma
membrane integrity was lost (e.g. Fig. 5A compared to Fig. 5E). The
loss of plasma membrane integrity after exposure to MLT peptides for
30 min is shown in Fig. 6A. F-MLT appeared to be more active than
the mutant MLT(14C)-F at 0.3 μM, which indicates the importance of
the proline residue for activity. Vesiculation of the cell membrane
(indicated by arrows in Fig. 6B) occurred in cells exposed to native
MLT at 0.1 and 0.3 μMconcentration, which correspondswith its higher
antimicrobial activity (Table 1) and cytotoxicity (Fig. 4B). The
concentration and type of added peptide affected plasma membrane
integrity (Fig. 6A). At 0.3 μM, F-MLT uptake was more than that of
MLT (P14C)-F, which suggests that proline may play a role in the
disruption of cell membranes and uptake of MLT peptides by live cells.
However, with 1 μM of MLT peptides, the plasma membrane integrity
was completely lost. In addition, distribution of peptides on the cell
surface also depended on peptide concentration which affected cell
membrane vesiculation and, consequently, blebbing. According to
Fig. 5, the MLT analogues caused loss of membrane integrity and
performing the experiments for a further 30 min gave similar results.A
B
(i) 0.1 M MLT
(ii) 0.3 M MLT
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Fig. 6. Analysis of ﬂuorescence microscopy of HeLa cells after treatment with F-MLT and
MLT(P14C)-F. (A) Cell membrane integrity following 30 min MLT treatment at 0 μM
(striped bar) 0.1 μM (clear bar), 0.3 μM (gray bar), and 1 μM (black bar) was determined
by measuring the ﬂuorescence intensity of the Cell Mask Deep Red dye (Fig. 5) using
ImageJ analysis software and plotted (*P b 0.05 or **P b 0.01 vs. untreated cells).
(B) Fluorescence microscopy of HeLa cells after treatment for 30 min with unlabeled
MLT at 0.1 (i) or 0.3 μM (ii). Arrow indicates bleb formation. No peptide AlexaFluor 430
was detected in the green channel (left image); Hela cell integrity was imaged using
phase contrast (middle panel images), and Cell Mask Deep Red dye in the red channel
(right panel images). Experiments repeated 2–4 times gave similar results. The scale bar
represents 20 μm.Although membrane integrity was dependent on concentration and
incubation time, both ﬂuorescent peptides (native and mutant) had
similar effects on HeLa cells.
3.7. Use of light microscopy to determine the effect of MLT peptides on HeLa
cells
Light microscopy was used to observe the surface of HeLa cells
following 15 min exposure to MLT and analogues. Cytoplasmic blebs
form when the cytoskeleton detaches from plasma membranes and
happens in both necrotic and apoptotic cells [52,53]. Although the
mechanism of bleb formationmay differ, actin is proposed to be respon-
sible [54]. Lightmicroscopic examination showed that MLT appeared to
be more toxic (Fig. 7H–J), causing almost 100% cell death after 15 min
incubation while the other peptides had less effect (Fig. 7B–G). Blebs
were detected after incubating HeLa cells with MLT peptides and the
overall cell morphology was also affected. The acquired images showed
that changes in morphology were evident after treating the cells with
0.1 μM of peptides. Increasing peptide concentration and incubation
time resulted in cell collapse, which was often followed by cytoplasmic
leakage and cell fragmentation. Monitoring blebs in plasma membrane
and detaching cells indicated that the cells were under stress or in some
stage of apoptosis or necrosis [54], which correlates with those of the
cytotoxicity assay (Fig. 5). Different forms of MLT showed different
effects (Fig. 8). For example, native MLT induced more blebbing and
caused cell death at lower levels than its analogues and membrane
blebbing rather than loss of membrane integrity was induced in the
earlier stages of the assay. Different types of blebs [55] were observed
when HeLa cells were exposed to MLT peptides with apoptotic blebs
at lower concentration and necrotic blebs at higher concentration of
peptides (Fig. 7).
4. Conclusions
MLT analogues were synthesized and labeled with a ﬂuorescent
probe to investigate their cytotoxic mechanism of action using model
synthetic membrane preparations, bacteria and HeLa cells. The effect
of single mutation (P14C) on the action mechanism of MLT was
investigated by microscopy, and measurements of MIC, cytotoxicity
and hemolysis. The ﬁnding that native MLT was more hemolytic and
cytotoxic at low concentrations (1 μM) than MLT(P14C) suggested
that proline may play a role in these activities. However, both ﬂuores-
cent MLT analogues caused cell membrane disruption, indicating that
the cell response was similar and that the ﬂuorescent label inﬂuenced
the behavior of the peptides.
The cytotoxicity of unlabeledMLTwas quite evident on HeLa cells at
0.1 μM. Treating these cells with the unlabeled MLT peptide led to the
formation of plasma membrane blebs which are a dynamic feature of
cellular reorganization [34] and relate to the cells' motility and cytoki-
nesis [52]. In addition, the ﬂuorescence images of the Cell Mask Deep
Red dye, which reports on the integrity of the cell membrane, showed
a concentration and time dependent decrease following exposure to
MLT. This indicates that phospholipid depletion occurred and led to
plasmamembrane disruption that represents the ﬁrst step of cell injury
duringMLT exposure. Other morphological changes, including blebbing
of the HeLa cells, were evident followingMLT exposure and suggest the
followingmechanisms: (1) cell membrane disruption from the actin cy-
toskeleton, (2) unfolding of invaginations in the membrane, (3) ﬂow of
lipids into the bleb through the bleb neck, and/or (4) vesicle fusion to
the membrane in the vicinity of a growing bleb [56].
Two key ﬁndings were identiﬁed when we examined the structure-
function relationship ofMLT. A ﬂuorescent tag placed at the N-terminus
ofMLT peptide caused the peptide to have diminished cytotoxic proper-
ties compared to the unlabeled peptide. This may be explained by the
CD spectroscopic results which showed that the ﬂuorescent label
altered the secondary structure of the MLT peptide causing it to be
A B C D
E F G
H I J
Fig. 7. Light microscopy of HeLa cells following treatment with 0.1, 0.3 or 1 μM peptide for 15 min. (A) untreated HeLa cells, and cells treated with: F-MLT (B-D), MLT(P14C)-F (E-G) or
native MLT (H-J). Green channel ﬂuorescence was overlaid onto the phase contrast cells. The arrows indicate bleb formation with the small arrows pointing to necrotic blebs and larger
arrows indicating apoptotic blebs. Scale bar = 20 μm.
2038 E. Jamasbi et al. / Biochimica et Biophysica Acta 1848 (2015) 2031–2039more structured. Secondly, the mutant MLT(P14C) peptide had
dramatically reduced antimicrobial activity compared to MLT and F-
MLT. Finally, the mutant MLT(P14C)-F had diminished binding and
uptake intoHeLa cells compared to F-MLT and therewas lessmembrane
blebbed cells with the mutant peptide, suggesting that the proline has
an important role in mediating binding to cells. However, it is not
known if membrane blebbing is a response of the cell to pore formation
by MLT or vice versa. Although the membrane is the ﬁrst target of MLT,
further studies are needed to determine if MLT is internalized and, if so,
which part of the cell is the target. The comparison between the effect of
MLTpeptides onGUVs and live cells indicated that themembrane of live0
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Fig. 8. Analysis of light microscopy of HeLa cells after treatment with MLT, F-MLT or
MLT(P14C)-F. % cell membrane blebbing following 15 min peptide treatment at 0 μM
(striped bar) 0.1 μM (clear bar), 0.3 μM (gray bar), and 1 μM (black bar) was determined
by counting number of blebbed cell using ImageJ analysis software. Results are mean ±
SEM.cells is damaged byMLT peptides to a greater extent than GUV bilayers.
Since MLT activity depends on the lipid composition of its targets,
further study using negatively charged GUVs to compare with these
and earlier studies using zwitterionic lipids [37] may help shed further
light on its mechanism of membrane action, in particular, using
correlated AFM-ﬂuorescence approaches [57] to examine peptide–
lipid interactions.
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